血必净注射液治疗脓毒症心肌损伤前瞻性队列研究OA
Effects of Xuebijing Injection in Sepsis-Induced Myocardial Injury:A Prospective Cohort Study
目的 探讨血必净注射液对不同炎症免疫表型脓毒症心肌损伤患者的差异化疗效.方法 采用前瞻性队列研究设计,纳入2025年1月—2026年5月南京医科大学附属淮安第一医院急诊医学科收治的脓毒症心肌损伤患者120例.根据是否接受血必净治疗并采用倾向性评分匹配(PSM)后分为血必净组(40例)和常规治疗组(40例),根据免疫表型分型分为高炎症型及免疫抑制型进行分层分析.主要结局为治疗第7天左心室整体纵向应变(GLS)变化值(ΔGLS);次要结局包括心肌损伤标志物、炎症因子及28天病死率.结果 所有患者均完成研究并纳入统计学分析.与本组治疗前比较,两组治疗后GLS升高,高敏肌钙蛋白I(hs-cTnI)、N末端B型利钠肽前体(NT-proBNP)、肿瘤坏死因子α(TNF-α)、白细胞介素(IL)-6降低(P<0.05)血必净组IL-10升高(P<0.05).与常规治疗组同期比较,血必净组治疗7天GLS 升高,hs-cTNI、NT-proBNP、TNF-α、IL-6 降低,IL-10 升高(P<0.05);治疗 7 天 ΔGLS 升高增大,hs-cTNI、NT-proBNP、TNF-α、IL-6降低增大(P<0.05,P<0.01).高炎症表型和免疫抑制表型中上述指标变化一致.血必净组28天死亡率[15.0%(6/40)]低于常规组[35.0%(14/40),P=0.02];高炎症表型结果[血必净组5.9%(1/17)vs.常规组37.5%(6/16),P=0.019]一致;但免疫抑制表型中两组死亡率[血必净组21.7%(5/23)vs.常规组33.3%(8/24)]比较,差异无统计学意义(P>0.05).结论 血必净可改善脓毒症心肌损伤患者的心功能及28天死亡率,其中高炎症型患者获益更为显著,其机制可能与抑制过度炎症及重建免疫稳态有关.
Objective To investigate the differential therapeutic effects of Xuebijing Injection(XBJ)in septic patients with myocardial injury across distinct inflammatory and immune phenotypes.Methods This prospective cohort study enrolled 120 patients with sepsis induced myocardial injury admitted to the Department of Emergency Medicine,Huai'an First People's Hospital affiliated with Nanjing Medical University,between January 2025 and May 2026.After propensity score matching(PSM),patients were categorized into an XBJ treatment group(40 cases)and a conventional treatment group(40 cases)based on whether the patients received XBJ treatment.Patients were further stratified according to immune-inflammatory phenotypes into hyperinflammatory and immunosuppressed subgroups for phenotype-based analyses.The primary outcome was the change in left ventricular global longitudinal strain(ΔGLS)from baseline to day 7 after treatment.Secondary outcomes included changes in myocardial injury biomarkers,inflammatory cytokines,and 28-day mortality.Results All enrolled patients completed the study and were included in the final statistical analysis.Compared with baseline,both groups showed increased GLS and decreased levels of high-sensitivity cardiac troponin I(hs-cTnI),N-terminal pro-B-type natriuretic peptide(NT-proBNP),tumor necrosis factor-α(TNF-α),and interleukin(IL)-6 after treatment(P<0.05).IL-10 levels significantly increased in the XBJ group(P<0.05).Compared with the conventional treatment group,patients receiving XBJ exhibited greater increases in GLS,reduced levels of hs-cTnI,NT-proBNP,TNF-α,and IL-6,and increased IL-10 levels at day 7(P<0.05).Moreover,the magnitude of improvement in ΔGLS and reductions in hs-cTnI,NT-proBNP,TNF-α,and IL-6 were significantly greater in the XBJ group(P<0.05,P<0.01).Similar trends were observed in both the hyperinflammatory and immunosuppressed phenotypes.The 28-day mortality rate was significantly lower in the XBJ group than in the conventional treatment group[15.0%(6/40)vs.35.0%(14/40),P=0.02].This survival benefit was particularly evident among patients with the hyperinflammatory phenotype[5.9%(1/17)vs.37.5%(6/16),P=0.019].However,among patients with the immunosuppressed phenotype,no significant difference in 28-day mortality was observed between the XBJ and conventional treatment groups[21.7%(5/23)vs.33.3%(8/24),P>0.05].Conclusions XBJ treatment improves cardiac function,attenuates myocardial injury,and reduces 28-day mortality in patients with sepsis-induced myocardial injury.Patients with a hyperinflammatory phenotype appear to derive greater clinical benefit,potentially due to the suppression of excessive inflammatory responses and restoration of immune homeostasis.
严专;吴魏芹;孙青松;高利利;石朋先;赵红梅;高素敏;陈亮
南京医科大学附属淮安第一医院急诊医学科(江苏 223300)||南京中医药大学金陵临床医学院急诊科(南京 210002)南京医科大学附属淮安第一医院急诊医学科(江苏 223300)南京医科大学附属淮安第一医院急诊医学科(江苏 223300)南京医科大学附属淮安第一医院急诊医学科(江苏 223300)南京医科大学附属淮安第一医院急诊医学科(江苏 223300)南京医科大学附属淮安第一医院急诊医学科(江苏 223300)南京医科大学附属淮安第一医院急诊医学科(江苏 223300)南京医科大学附属淮安第一医院急诊医学科(江苏 223300)
脓毒症心肌损伤血必净注射液免疫分型前瞻性队列研究
sepsismyocardial injuryXuebijing Injectionimmune phenotypingprospective cohort study
《中国中西医结合杂志》 2026 (8)
916-923,8
中国博士后科学基金面上资助项目(No.2020M671387)淮安市卫生健康科研面上项目(No.HAWJ2024007)南京医科大学苏北临床医学研究院科研创新团队项目(No.YLCT202004,No.YCT202302)
评论